GLI1 and neoplasm: Consistent findings were also revealed upon further investigation in vivo, where the concurrent inhibition of GLI and PI3K/AKT/mTOR signaling in mouse subcutaneous xenograft model enhances tumors’ sensitivity to cisplatin, as indicated by reduced tumor burden [102].